Inventor · disambiguated record
Mark Cobbold
Also filed as: COBBOLD MARK · COBBOLD MARK TEMPLE
22 granted patents·25 pending applications·480 citations·filing 1999–2024
95Inventor score
Files withUNIV BIRMINGHAM10UNIV VIRGINIA PATENT FOUNDATION8MASSACHUSETTS GEN HOSPITAL6ASTRAZENECA AB5COBBOLD MARK3
Top patents by PatentIndex Score
47 records- 0196US6788681B1Virtual private networks and methods for their operationNORTEL NETWORKS LTD·Filed 2000·Granted Sep 7, 2004·288 cites·46 claims
- 0293US8340890B1Method and apparatus for enabling commuter groupsCOBBOLD MARK·Filed 2012·Granted Dec 25, 2012·17 cites·20 claims
- 0393US8150608B2Method and apparatus for enabling commuter groupsCOBBOLD MARK·Filed 2011·Granted Apr 3, 2012·17 cites·18 claims
- 0492US7974771B2Method and apparatus for enabling commuter groupsNORTEL NETWORKS LTD·Filed 2006·Granted Jul 5, 2011·25 cites·19 claims
- 0591US8660781B2Method and apparatus for enabling commuter groupsROCKSTAR CONSORTIUM US LP·Filed 2012·Granted Feb 25, 2014·10 cites·21 claims
- 0689US10035856B2Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cellsREVITOPE LTD·Filed 2016·Granted Jul 31, 2018·11 cites·16 claims
- 0788US10106621B2Immunotherapeutic molecules and usesUNIV BIRMINGHAM·Filed 2017·Granted Oct 23, 2018·6 cites·14 claims
- 0887US9822180B2Immunotherapeutic molecules and usesUNIV BIRMINGHAM·Filed 2013·Granted Nov 21, 2017·8 cites·20 claims
- 0986US11578115B2Chimeric antigen receptors based on alternative signal 1 domainsMASSACHUSETTS GEN HOSPITAL·Filed 2018·Granted Feb 14, 2023·3 cites·28 claims
- 1085US11236131B2Re-directed immunotherapyUNIV BIRMINGHAM·Filed 2019·Granted Feb 1, 2022·1 cites·22 claims
- 1185US9358282B2Re-directed immunotherapyUNIV BIRMINGHAM·Filed 2015·Granted Jun 7, 2016·4 cites·26 claims
- 1284US9402916B2Re-directed immunotherapyCOBBOLD MARK·Filed 2012·Granted Aug 2, 2016·6 cites·17 claims
- 1380US10287321B2Re-directed immunotherapyUNIV BIRMINGHAM·Filed 2015·Granted May 14, 2019·2 cites·21 claims
- 1479US9650445B2Immunotherapeutic molecules and usesUNIV BIRMINGHAM·Filed 2015·Granted May 16, 2017·2 cites·16 claims
- 1576US9561266B2Target peptides for immunotherapy and diagnosticsU VA LICENSING & VENTURES GROUP·Filed 2013·Granted Feb 7, 2017·5 cites·18 claims
- 1672US10682399B2Target peptides for colorectal cancer therapy and diagnosticsUNIV VIRGINIA PATENT FOUNDATION·Filed 2013·Granted Jun 16, 2020·2 cites·101 claims
- 1771US12042530B2Target peptides for immunotherapy and diagnosticsUNIV VIRGINIA PATENT FOUNDATION·Filed 2021·Granted Jul 23, 2024·0 cites·7 claims
- 1869US6952396B1Enhanced dual counter rotating ring network control systemNORTEL NETWORKS LTD·Filed 1999·Granted Oct 4, 2005·73 cites·53 claims
- 1969US2014172289A1Method and apparatus for enabling commuter groupsROCKSTAR CONSORTIUM US LP·Filed 2014·Application pending·0 cites
- 2067US2022041655A1Class i mhc phosphopeptides for cancer immunotherapy and diagnosisAGENUS INC·Filed 2021·Application pending·0 cites
- 2167US2023250150A1Chimeric antigen receptors based on alternative signal 1 domainsMASSACHUSETTS GEN HOSPITAL·Filed 2022·Application pending·0 cites
- 2265US2025115678A1T cell binding compositions and methodsASTRAZENECA AB·Filed 2024·Application pending·0 cites
- 2364US12459975B2Modified T cells and methods of their useMASSACHUSETTS GEN HOSPITAL·Filed 2018·Granted Nov 4, 2025·0 cites·17 claims
- 2463US2024316106A1Methods for generating primary immune cellsASTRAZENECA AB·Filed 2024·Application pending·0 cites
- 2563US2025346681A1T cell binding proteinsASTRAZENECA AB·Filed 2023·Application pending·0 cites
- 2662US12419913B2Modification of CAR-T cellsDNA TWOPOINTO INC·Filed 2023·Granted Sep 23, 2025·0 cites·20 claims
- 2761US2024350630A1Compositions and methods of treating disease with chimeric antigen receptors to b cell maturation antigen (bcma)ASTRAZENECA AB·Filed 2024·Application pending·0 cites
- 2860US2021154279A1Target peptides for colorectal cancer therapy and diagnosticsUNIV VIRGINIA PATENT FOUNDATION·Filed 2020·Application pending·0 cites
- 2954US2023279352A1Methods for generating primary immune cellsASTRAZENECA AB·Filed 2022·Application pending·0 cites
- 3054US2020016262A1Targeting Moiety Peptide Epitope Complexes Having a Plurality of T-Cell EpitopesUNIV BIRMINGHAM·Filed 2019·Application pending·0 cites
- 3153US2018346568A1Functional Antibody Fragment Complementation for a Two-Components System for Redirected Killing of Unwanted CellsREVITOPE LTD·Filed 2018·Application pending·0 cites
- 3252US2015297745A1Agents and MethodsUNIV BIRMINGHAM·Filed 2013·Application pending·0 cites
- 3350US2018066017A1Class i mhc phosphopeptides for cancer immunotherapy and diagnosisAGENUS INC·Filed 2017·Application pending·0 cites
- 3449US2021269547A1Antibody tumor-targeting assembly complexesMASSACHUSETTS GEN HOSPITAL·Filed 2019·Application pending·0 cites
- 3548US2022265791A1Target peptides for cancer therapy and diagnosticsUNIV VIRGINIA PATENT FOUNDATION·Filed 2020·Application pending·0 cites
- 3648US2017333541A1Target peptides for immunotherapy and diagnosticsUNIV VIRGINIA PATENT FOUNDATION·Filed 2016·Application pending·0 cites
- 3747US2013259883A1Class i mhc phosphopeptides for cancer immunotherapy and diagnosisHUNT DONALD F·Filed 2011·Application pending·0 cites
- 3847US2022387567A1Compositions and methods for treating diseases and disorders associated with aberrant regulation of proteinsUNIV VIRGINIA PATENT FOUNDATION·Filed 2020·Application pending·0 cites
- 3946US10441649B2Targeting moiety peptide epitope complexes having a plurality of T-cell epitopesUNIV BIRMINGHAM·Filed 2016·Granted Oct 15, 2019·0 cites·16 claims
- 4045US2022170044A1Transposon-based modifications of immune cellsDNA TWOPOINTO INC·Filed 2020·Application pending·0 cites
- 4144US10394603B2Virtual container processing on high performance computing processorsGENBAND US LLC·Filed 2017·Granted Aug 27, 2019·0 cites·17 claims
- 4244US2021220337A1Methods of modulating antigenicity to enhance recognition by t-cellsMASSACHUSETTS GEN HOSPITAL·Filed 2019·Application pending·0 cites
- 4343US2011229908A1Methods and products for measuring free immunoglobulin light chain moleculesJEFFERIS ROYSTON·Filed 2009·Application pending·0 cites
- 4441US2022323600A1Teac and attac immunooncology compositions and methodsMASSACHUSETTS GEN HOSPITAL·Filed 2020·Application pending·0 cites
- 4538US2019015494A1Identification of class i mhc associated glycopeptides as targets for cancer immunotherapyUNIV VIRGINIA PATENT FOUNDATION·Filed 2016·Application pending·0 cites
- 4637US2016206726A1ImmunotherapyUNIV BIRMINGHAM·Filed 2015·Application pending·0 cites
- 4737US2019374627A1Target peptides for cancer therapy and diagnosticsUNIV VIRGINIA PATENT FOUNDATION·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mark Cobbold files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →